Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

Darron R. Brown, Kenneth H. Fife, Cosette M. Wheeler, Laura A. Koutsky, Lisa M. Lupinacci, Radha Railkar, Gretchen Suhr, Eliav Barr, Anthony Dicello, Weili Li, Judith F. Smith, Amha Tadesse, Kathrin U. Jansen

Research output: Contribution to journalArticle

82 Scopus citations

Abstract

A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was given at 0, 2 and 6 months. HPV16 infection was defined by positive polymerase chain reaction (PCR) results following vaccination. The incidence of HPV infection was observed to be 0 cases per 100 person-years at risk in the vaccine group, and 5 cases per 100 person-years at risk in the control group. These results support the institution of larger efficacy trials for HPV L1 VLP vaccines.

Original languageEnglish (US)
Pages (from-to)2936-2942
Number of pages7
JournalVaccine
Volume22
Issue number21-22
DOIs
StatePublished - Jul 29 2004

Keywords

  • Human papillomavirus
  • Polymerase chain reaction
  • Vaccination
  • Virus-like particle

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Fingerprint Dive into the research topics of 'Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine'. Together they form a unique fingerprint.

  • Cite this

    Brown, D. R., Fife, K. H., Wheeler, C. M., Koutsky, L. A., Lupinacci, L. M., Railkar, R., Suhr, G., Barr, E., Dicello, A., Li, W., Smith, J. F., Tadesse, A., & Jansen, K. U. (2004). Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine, 22(21-22), 2936-2942. https://doi.org/10.1016/j.vaccine.2003.11.059